Key result
Novel enterovirus B antivirals show strong in vitro activity but face persistent clinical translation hurdles.
Why the study?
Enterovirus B-related diseases can be life threatening in high-risk populations, but treatment remains largely supportive with no selective antivirals commercially available.
This review highlights ongoing medicinal chemistry efforts and novel targets for developing enterovirus B antivirals, emphasizing the need for broad-spectrum agents that overcome viral resistance.
No enterovirus B antivirals are clinically available; leaves open broad-spectrum development targeting replication and host factors.
Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market. As their clinical relevance has become more serious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antivirals with very high selectivity indexes and promising in vitro activities have been discovered. The scope of this review encompasses recent advances in the discovery of new compounds with anti-viral activity against EV-B, as well as further progress in repurposing drugs to treat these infections. Current progress and future perspectives in drug discovery against EV-Bs are briefly discussed and existing gaps are spotlighted.
No takes yet. Share an insight, caveat, or question.
Tammaro et al. (2023) conducted a review in Enterovirus B (EV-B) infections. Direct-acting and host-targeting antivirals was evaluated. Recent advances in drug discovery against enterovirus B infections have yielded numerous potential antivirals with promising in vitro activities, although clinical translation remains challenging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: